313 completed, 33 terminated, 31 unknown, 17 recruiting. 433 Phase 2, 87 Phase 1, 68 Phase 3.
Follow Parasitic Diseases: new trials by email Literature Review of Parasitic Diseases trials Research Report on Parasitic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oxfendazole in Mild Parenchymal Brain Cysticercosis Oxfendazole single dose, Oxfendazole three doses, albendazole plus praziquantel regime - Brain Cysticercosis | Phase 2 / Phase 3 | Not yet recruiting | Universidad Peruana Cayetano Heredia | 544 | 2026-12-01 | 2026-05-01 |
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax | Phase 2 | Not yet recruiting | R. Kiplin Guy | 104 | 2026-12-01 | 2026-10-21 |
| Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 220 | 2026-11-17 | 2026-11-12 |
| Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita Emodepside, Albendazole 400 mg - Trichuris Infection | Phase 2 | Not yet recruiting | Jennifer Keiser | 100 | 2026-11-15 | 2026-08-14 |
| Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni | Phase 2 / Phase 3 | Not yet recruiting | Rhode Island Hospital | 600 | 2026-11-01 | 2026-08-12 |
| A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg - Malaria, Falciparum | Phase 2 | Recruiting | GlaxoSmithKline | 70 | 2026-10-07 | 2026-11-10 |
| Tafenoquine Drug Levels in Small Children Chloroquine, Tafenoquine - Plasmodium Vivax Malaria, Vivax Malaria | Phase 2 | Not yet recruiting | University of Oxford | 20 | 2026-09-01 | 2026-09-22 |
| One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis Oxfendazole, Triclabendazole - Fascioliasis | Phase 2 | Not yet recruiting | Universidad Peruana Cayetano Heredia | 336 | 2026-08-15 | 2026-06-03 |
| PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali PfSPZ-LARC2 Vaccine, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Sanaria Inc. | 300 | 2026-07-20 | 2026-07-23 |
| Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride) - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Sanaria Inc. | 180 | 2026-05-04 | 2026-06-01 |
| Postpartum 8-aminoquinoline Breast Milk Study Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort - Drug Pharmacokinetics in Healthy Volunteers | Phase 2 / Phase 3 | Not yet recruiting | Curtin University | 60 | 2026-04-01 | 2026-03-18 |
| L9LS-R21 Interaction Single dose of 1800 mg L9LS SC (12mL), Placebo 12 mL SC, Single dose of 225 mg L9LS SC (1.5mL) - Malaria | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-03-01 | 2026-04-09 | |
| Dose Finding Trial of R21/Matrix-M in School Children 5µg R21/50µg Matrix-M, 10µg R21/50µg Matrix-M - Malaria (Plasmodium Falciparum) | Phase 2 | Active not recruiting | University of Oxford | 40 | 2026-02-18 | 2026-08-24 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-02-12 | 2026-10-15 |
| Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Victoria Biomedical Research Institute | 1116 | 2026-01-20 | 2026-06-29 |
| Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia PvCS/Montanide ISA-51 VG Vaccine, Placebo - Montanide ISA-51 VG Adjuvant Alone - Plasmodium Vivax Malaria, Plasmodium Vivax Infection | Phase 2 | Not yet recruiting | Malaria Vaccine and Drug Development Center | 72 | 2026-01-19 | 2026-01-28 |
| The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children Echinacea Extract - Cryptosporidium Infection | Phase 2 | Recruiting | Al-Azhar University | 60 | 2026-01-18 | 2026-02-05 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M R21, RH5.1, R78C - Malaria,Falciparum | Phase 2 | Active not recruiting | University of Oxford | 360 | 2025-12-15 | 2026-10-21 |
| Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo - Cryptosporidiosis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 80 | 2025-12-08 | 2026-11-10 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) KAE609 (Cipargamin), SoC (Coartem), INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 95 | 2025-10-10 | 2026-09-10 |
Showing 20 of 433. Sign in to see all of them.
Malaria (177) · Malaria, Falciparum (108) · Leishmaniasis, Cutaneous (40) · Malaria, Vivax (29) · Leishmaniasis (27) · Chagas Disease (15) · Schistosomiasis (13) · Leishmaniasis, Mucocutaneous (12) · Trichuriasis (11) · HIV Infections (9) · Hookworm Infections (9) · Leishmaniasis, Visceral (9) · Lice Infestations (8) · Onchocerciasis (8)
Infections (427) · Vector Borne Diseases (362) · Protozoan Infections (353) · Mosquito-Borne Diseases (252) · Euglenozoa Infections (86) · Skin and Connective Tissue Diseases (82) · Skin Diseases (80) · Skin Diseases, Infectious (80) · Skin Diseases, Parasitic (77) · Malaria (70) · Helminthiasis (56) · Leishmaniasis (36) · Nematode Infections (36) · Secernentea Infections (31)
Albendazole (23) · Artemether, Lumefantrine Drug Combination (23) · Primaquine (22) · miltefosine (19) · Chloroquine (18) · Ivermectin (18) · fanasil, pyrimethamine drug combination (16) · Artesunate (15) · Azithromycin (15) · Amodiaquine (14) · tafenoquine (12) · Meglumine Antimoniate (11) · Saline Solution (11) · NITD 609 (9) · Praziquantel (9)
University of Oxford (41) · National Institute of Allergy and Infectious Diseases (NIAID) (31) · U.S. Army Medical Research and Development Command (28) · GlaxoSmithKline (21) · London School of Hygiene and Tropical Medicine (21) · Drugs for Neglected Diseases (16) · Novartis Pharmaceuticals (16) · Medicines for Malaria Venture (13) · Jennifer Keiser (8) · Pfizer (8) · Oswaldo Cruz Foundation (7) · Sanaria Inc. (7) · Heidelberg University (6) · Hospital Universitário Professor Edgard Santos (6) · Malaria Vaccine and Drug Development Center (5)
United States (51) · Kenya (36) · Burkina Faso (35) · Mali (32) · Brazil (28) · Gabon (23) · Uganda (21) · United Kingdom (21) · Thailand (20) · Tanzania (18) · Colombia (16) · Ghana (16) · Bolivia (14) · Democratic Republic of the Congo (14) · India (13)
Kassoum Kayentao, MD, MPH, PhD (5) · Adrian VS Hill, D.Phil, FRCP (4) · James McCarthy, Prof (4) · Adrian V S Hill, MD (3) · Brian Greenwood, FRCP, FRS (3) · Patrick E Duffy, M.D. (3) · Peter Crompton, MD, MPH (3) · Shyam Sundar, MD (3) · Adrian V Hill, DPhill FRCP (2) · Adrian VS Hill, MA, BM BCh, DPhil, DM (2) · Afif Ben Salah, M.D., Ph.D. (2)
PMID 39377226, PMID 28495354, PMID 19150418, PMID 2022660, PMID 21298114, PMID 21443960, PMID 23284726, PMID 23433102, PMID 23877689, PMID 23899517, PMID 23962071, PMID 25211344, PMID 26292027, PMID 26292257, PMID 26571311, PMID 26881924, PMID 27695088, PMID 28472957, PMID 29324864, PMID 31672143, PMID 33998661, PMID 34179977, PMID 35664997, PMID 36875126, PMID 41176969, PMID 10190913, PMID 10501745, PMID 11832638, PMID 12011004, PMID 12663340, PMID 15069048, PMID 15838784, PMID 16338450, PMID 16503464, PMID 16904798, PMID 17213921, PMID 17442466, PMID 17707447, PMID 17845167, PMID 18231580, PMID 18270560, PMID 18286187, PMID 18320064, PMID 18419347, PMID 18545693, PMID 18694333, PMID 18752443, PMID 18781879, PMID 19098989, PMID 19262754
2016 (4), 2015 (2), R01NS074409 (2), 2014 (1), R01AI041735 (1), R01AI045468 (1), R01AI170564 (1), R01AI184979 (1), R01HD095562 (1), R01HL086488 (1), R01MH092226 (1), R01NS054805 (1), R01NS102176 (1), U01AI065683 (1), U01AI129783 (1)